<DOC>
<DOCNO>EP-0639586</DOCNO> 
<TEXT>
<INVENTION-TITLE>
Phosphonic acid derivatives, process for their preparation and pharmaceutical compositions comprising them
</INVENTION-TITLE>
<CLASSIFICATIONS>C07K5062	A61P910	A61P900	C07K1113	C07K100	C07K506	C07K106	C07K122	A61P912	C07F9572	A61K3800	A61K3855	C07F924	C07K500	A61K3800	A61K3855	C07F900	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>C07K	A61P	A61P	C07K	C07K	C07K	C07K	C07K	A61P	C07F	A61K	A61K	C07F	C07K	A61K	A61K	C07F	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>C07K5	A61P9	A61P9	C07K1	C07K1	C07K5	C07K1	C07K1	A61P9	C07F9	A61K38	A61K38	C07F9	C07K5	A61K38	A61K38	C07F9	</CLASSIFICATIONS-FOURTH>
<APPLICANTS>
<APPLICANT-NAME>
ADIR
</APPLICANT-NAME>
<APPLICANT-NAME>
ADIR ET COMPAGNIE
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
DE NANTEUIL GUILLAUME
</INVENTOR-NAME>
<INVENTOR-NAME>
REMOND GEORGES
</INVENTOR-NAME>
<INVENTOR-NAME>
VERBEUREN TONY
</INVENTOR-NAME>
<INVENTOR-NAME>
DE NANTEUIL, GUILLAUME
</INVENTOR-NAME>
<INVENTOR-NAME>
REMOND, GEORGES
</INVENTOR-NAME>
<INVENTOR-NAME>
VERBEUREN, TONY
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
Compounds of formula (I):


wherein:

R
1
 represents a hydroxy group, a linear or branched (C
1
-C
6
)alkoxy group or an amino
group (unsubstituted or substituted by 1 or 2 linear or branched (C
1
-C
6
)alkyl groups),
R
2
 represents a linear or branched (C
1
-C
6
)alkyl group unsubstituted or substituted by a
phenyl or (C
3
-C
7
)cycloalkyl group,
X
1
 represents -NH-,
X
2
 represents -O-,
R
3
 represents a hydrogen atom, a linear or branched (C
1
-C
6
)alkyl group or a phenyl
group,
R
4
 represents a linear or branched (C
1
-C
6
)alkyl group always substituted by one or more
identical or different groups: hydroxy, benzyloxy, benzyloxycarbonylamino, amino,

mono- or di-(C
1
-C
6
)alkylamino in which the(each) alkyl moiety is linear or branched,
acetoxy, 2,2-dimethyl-1,3-dioxolan-4-yl, 
R
5
 represents an indol-3-ylmethyl, naphthylmethyl, linear or branched (C
1
-C
6
)alkyl,
phenyl or benzyl group,

their enantiomers, diastereoisomers and epimers and addition salts thereof with a
pharmaceutically acceptable acid or base.
Compounds of formula (I) according to claim 1 wherein R
4
 represents a
(C
1
-C
6
)alkyl group always substituted by one or more hydroxy groups, their enantiomers,
diastereoisomers and epimers and addition salts thereof with a pharmaceutically

acceptable acid or base.
Compounds of formula (I) according to claim 1, wherein R
5
 represents an indol-3-ylmethyl
group, their enantiomers, diastereoisomers and epimers and addition salts

thereof with a pharmaceutically acceptable acid or base.
Compound of formula (I) according to claim 1 which is N-[(2,3-dihydroxypropoxy)hydroxyphosphinyl]-(S)Leu-(S)Trp-OH,

its isomers and addition salts thereof
with a pharmaceutically acceptable acid or base.
Process for the preparation of compounds of formula (I) according to claim 1,
characterised in that there is used as starting material the amino acid of formula (II), in

racemic form or in the form of a pure enantiomer:


wherein: 

R'
1
 represents a linear or branched (C
1
-C
6
)alkoxy group or an amino group (unsubstituted
or substituted by 1 or 2 linear or branched (C
1
-C
6
)alkyl groups),

and
R
5
 is as defined for formula (I),

which is reacted with a compound of formula (III) in racemic form or in the form of a
pure enantiomer:



wherein R
2
 and X
1
 are as defined for formula (I) and P represents a suitable protecting
group,

to yield a compound of formula (IV), which is separated into its isomers, where
appropriate, according to a conventional separation technique:



wherein R'
1
, R
2
, X
1
, R
5
 and P are as defined hereinbefore,

which is deprotected, depending upon the nature of P, using a suitable technique, to yield
a compound of formula (V): 



wherein R'
1
, R
2
, R
5
 and X
1
 are as defined hereinbefore,

which is reacted:

in an inert medium, at room temperature, with a chloroformic solution prepared in
advance by stirring the following in an inert medium:
one equivalent of a phenyl dichlorophosphate of formula (VII):

one equivalent of a compound of formula (VIII):

R'
4
 - X
2
 - H

wherein

X
2
 is as defined for formula (I),
R'
4
 represents an alkyl group (substituted by one or more groups: benzyloxy, benzyloxycarhonylamino,
acetoxy or di-(C
1
-C
6
)alkylamino in which each alkyl moiety is linear or
branched or 2,2-dimethyl-1,3-dioxolan-4-yl), and
two equivalents of triethylamine,

to yield, after deprotection in a basic medium, a compound of formula (I/a), a particular
case of the compounds of formula (I):


 
wherein R'
1
, R
2
, R
5
 and X
2
 are as defined hereinbefore and R"
4
 represents an alkyl group
(substituted by one or more groups: hydroxy, benzyloxy, benzyloxycarbonylamino,

acetoxy or di-(C
1
-C
6
)alkylamino in which each alkyl moiety is linear or branched or 2,2-dimethyl-1,3-dioxolan-4-yl),

in which compound of formula (I/a) the group R"
4
 may be converted :

when that group represents an alkyl group substituted by one or more benzyloxy
groups, into an alkyl group substituted by one or more hydroxy groups, by

catalytic hydrogenation,
when that group represents an alkyl group substituted by one or more acetoxy
groups, into an alkyl group substituted by one or more hydroxy groups, by

reaction with lithium hydroxide or sodium hydroxide,

in which compound of formula (I/a):

the R'
1
 group, when that group represents an alkoxy group, may be converted into
the corresponding hydroxy group,

which compound of formula (I/a):

may be purified according to conventional purification techniques,
may be separated into its isomers according to conventional separation
techniques, and
may be converted into a corresponding salt of an acid or base.
Process for the preparation of the phosphoramidon of formula:

 
characterised in that it is identical to that described in claim 5, but replacing the

compound of formula (VIII) by the compound of formula:

Pharmaceutical composition comprising as active ingredient a compound
according to any one of claims 1 to 4, alone or in combination with one or more inert,

non-toxic, pharmaceutically acceptable excipients or carriers.
Pharmaceutical composition according to claim 7 comprising an active ingredient
according to any one of claims 1 to 4 for use as an endothelin convertase inhibitor.
</CLAIMS>
</TEXT>
</DOC>
